325 related articles for article (PubMed ID: 8294901)
1. The role of iron in senescence of dopaminergic neurons in Parkinson's disease.
Youdim MB; Riederer P
J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901
[TBL] [Abstract][Full Text] [Related]
2. The possible role of iron in the etiopathology of Parkinson's disease.
Youdim MB; Ben-Shachar D; Riederer P
Mov Disord; 1993; 8(1):1-12. PubMed ID: 8419792
[TBL] [Abstract][Full Text] [Related]
3. Iron transport in Parkinson's disease.
Hirsch EC
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
[TBL] [Abstract][Full Text] [Related]
4. The enigma of neuromelanin in Parkinson's disease substantia nigra.
Youdim MB; Ben-Shachar D; Riederer P
J Neural Transm Suppl; 1994; 43():113-22. PubMed ID: 7884393
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress indices in Parkinson's disease : biochemical determination.
Youdim MB; Drigues N; Mandel S
Methods Mol Med; 2001; 62():137-53. PubMed ID: 21318773
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and animal studies of Parkinson's disease.
Oertel WH; Kupsch A
Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
[TBL] [Abstract][Full Text] [Related]
7. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease.
Zecca L; Casella L; Albertini A; Bellei C; Zucca FA; Engelen M; Zadlo A; Szewczyk G; Zareba M; Sarna T
J Neurochem; 2008 Aug; 106(4):1866-75. PubMed ID: 18624918
[TBL] [Abstract][Full Text] [Related]
8. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
Mech Ageing Dev; 2005 Feb; 126(2):317-26. PubMed ID: 15621213
[TBL] [Abstract][Full Text] [Related]
9. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
10. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
11. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity.
Yantiri F; Andersen JK
IUBMB Life; 1999 Aug; 48(2):139-41. PubMed ID: 10794588
[TBL] [Abstract][Full Text] [Related]
12. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits.
Zhang J; Stanton DM; Nguyen XV; Liu M; Zhang Z; Gash D; Bing G
Neuroscience; 2005; 135(3):829-38. PubMed ID: 16165292
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
14. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
15. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
16. [Oxidative stress and the brain].
Tanaka M
Nihon Ronen Igakkai Zasshi; 1997 Sep; 34(9):706-10. PubMed ID: 9430979
[TBL] [Abstract][Full Text] [Related]
17. Dopaminergic neurons.
Chinta SJ; Andersen JK
Int J Biochem Cell Biol; 2005 May; 37(5):942-6. PubMed ID: 15743669
[TBL] [Abstract][Full Text] [Related]
18. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
19. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis.
Jellinger K; Kienzl E; Rumpelmair G; Riederer P; Stachelberger H; Ben-Shachar D; Youdim MB
J Neurochem; 1992 Sep; 59(3):1168-71. PubMed ID: 1494904
[TBL] [Abstract][Full Text] [Related]
20. Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease.
Marinova-Mutafchieva L; Sadeghian M; Broom L; Davis JB; Medhurst AD; Dexter DT
J Neurochem; 2009 Aug; 110(3):966-75. PubMed ID: 19549006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]